Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer
Phase 2
Not yet recruiting
- Conditions
- Advanced Ovarian Cancer
- Interventions
- Biological: AST-201Drug: PlaceboDrug: rhuGM-CSF(Granulocyte-Macrophage Colony-Stimulating Factor)
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2023-07-20
- Lead Sponsor
- Aston Sci. Inc.
- Target Recruit Count
- 98
- Registration Number
- NCT05794659
- Locations
- 🇺🇸
University of Washington, Seattle, Washington, United States
Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric Cancer
- First Posted Date
- 2023-03-16
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Aston Sci. Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05771584
- Locations
- 🇨🇳
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
🇨🇳Chi Mei Medical Center, Tainan, Taiwan
🇨🇳Taipei Veterans General Hospital, Taipei, Taiwan
Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer
Phase 2
Terminated
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2021-12-20
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Aston Sci. Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT05163223
- Locations
- 🇺🇸
Ironwood Cancer and Research Centers, Chandler, Arizona, United States
🇺🇸Scripps Health, La Jolla, California, United States
🇨🇳China Medical University Hospital, Taichung City, Taiwan
AST-021p Study in Advanced Solid Tumors
- First Posted Date
- 2021-04-28
- Last Posted Date
- 2023-07-20
- Lead Sponsor
- Aston Sci. Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT04864418
- Locations
- 🇰🇷
Korea University Anam Hospital, Seoul, Korea, Republic of
🇰🇷Seoul ST. Mary's Hospital, Seoul, Korea, Republic of
🇰🇷Korea University Guro Hospital, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath